Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Original) A compound according to Formula I, wherein

Formula I

X is O, NOH, NO(1-4C)alkyl, NO(1-4C)acyl;

A1-A5 are C, substituted with R1, or N, provided that at least one and not more than three of A1-A5 are N; or

one or two of A1, A2 and A5 are N, and the others are C, substituted with R1, and A3 and A4 together represent a fused benzo ring or a fused five- or six-membered nitrogen-containing aromatic ring, both optionally substituted with one or more halogen and/or (1-4C)alkyl;

each R1 is independently selected from H, halogen, (1-4C)alkyl and (1-4C)alkoxy;

R2 is H, (1-4C)alkyl, or (1-6C) alkenyl, both optionally substituted with an (6-10C)aryl group, which is optionally substituted with one or more halogen and/or (1-4C)alkyl; and

R3 is H or (1-4C)alkyl, optionally substituted with one or more halogen; and R4 is cyclopropyl or cyclopropenyl both optionally substituted with one or more halogen and/or (1-4C)alkyl; or

R2 together with R3 forms a 3-, 4-, 5- or 6-membered carbocyclic ring; and R4 is cyclopropyl or cyclopropenyl both optionally substituted with one or more halogen and/or (1-4C)alkyl); or

R2 is H or (1-4C)alkyl; and

R3 together with R4 forms a 5-, 6- or 7-membered saturated or unsaturated carbocyclic ring;

R5 is H or (1-4C)alkyl;

or a pharmaceutically acceptable salt and/or hydrate form and/or prodrug thereof.

- (Currently Amended) A compound according to claim 1 characterised in that wherein A1-A5 are C, substituted with R1, or N, provided that at least one and not more than three of A1-A5 are N.
- 3. (Currently Amended) A compound according to claim 1 characterised in that wherein one or two of A1, A2 and A5 are N, and the others are C, substituted with R1, and A3 and A4 together represent a fused benzo ring or a fused five- or six-membered nitrogen-containing aromatic ring, both optionally substituted with halogen and/or (1-4C)alkyl.
- (Currently Amended) A compound according to claim 1 characterised in that wherein

R2 is H, (1-4C)alkyl or (1-6C)alkenyl, both optionally substituted with an (6-10C)aryl group, which is optionally substituted with one or more halogen and/or (1-4C)alkyl; and

R3 is H or (1-4C)alkyl, optionally substituted with one or more halogen; and R4 is cyclopropyl or cyclopropenyl, both optionally substituted with one or more halogen and/or (1-4C)alkyl.

 (Currently Amended) A compound according to claim 1, characterised in that wherein

R2 together with R3 forms a 3-, 4-, 5- or 6-membered carbocyclic ring; and R4 is cyclopropyl or cyclopropenyl, both optionally substituted with one or more halogen and/or (1-4C)alkyl.

6. (Currently Amended) A compound according to claim 1, characterised in that wherein

R2 is H or (1-4C)alkyl; and

R3 together with R4 forms a 5-, 6- or 7-membered saturated or unsaturated carbocyclic ring.

 (Currently Amended) A compound according to claim 2, characterised in that wherein

R2 is H, (1-4C)alkyl or (1-6C)alkenyl, both optionally substituted with an (6-10C)aryl group, which is optionally substituted with one or more halogen and/or (1-4C)alkyl; and

R3 is H or (1-4C)alkyl optionally substituted with one or more halogen; and R4 is cyclopropyl or cyclopropenyl both optionally substituted with one or more halogen and/or (1-4C)alkyl.

8. (Currently Amended) A compound according to claim 2, characterised in that wherein

R2 together with R3 forms a 3-, 4-, 5- or 6-membered carbocyclic ring; and R4 is cyclopropyl or cyclopropenyl, both optionally substituted with one or more halogen and/or (1-4C)alkyl.

 (Currently Amended) A compound according to claim 2, characterised in that wherein

R2 is H or (1-4C)alkyl; and

R3 together with R4 forms a 5-, 6- or 7-membered saturated or unsaturated carbocyclic ring.

 (Currently Amended) A compound according to claim 3, characterised in that wherein

R2 is H, (1-4C)alkyl or (1-6C)alkenyl, both optionally substituted with an (6-10C)aryl group which is optionally substituted with one or more halogen and/or (1-4C)alkyl; and

R3 is H or (1-4C)alkyl optionally substituted with one or more halogen; and R4 is cyclopropyl or cyclopropenyl both optionally substituted with one or more halogen and/or (1-4C)alkyl.

11. (Currently Amended) A compound according to claim 3, characterised in that wherein

R2 together with R3 forms a 3-, 4-, 5- or 6-membered carbocyclic ring; and R4 is cyclopropyl or cyclopropenyl, both optionally substituted with one or more halogen and/or (1-4C)alkyl.

12. (Currently Amended) A compound according to claim 3, characterised in that

wherein

R2 is H or (1-4C)alkyl; and

R3 together with R4 forms a 5-, 6- or 7-membered saturated or unsaturated carbocyclic ring.

- (Currently Amended) A compound according to claim 1, characterised in that wherein X is O.
- (Currently Amended) A compound according to claim 4, characterised in that wherein R4 is cyclopropyl.
- (Currently Amended) A compound according to claim 5, characterised in that wherein R4 is cyclopropyl.
- 16. (Currently Amended) A compound according to claim 2, characterised in that wherein A1, A3, A4 and A5 are C, substituted with R1, and A2 is N.
- 17. (Cancelled)
- (Currently Amended) A compound according to claim 13, characterised in that wherein

A1, A3, A4 and A5 are C, substituted with R1, and A2 is N;

R2 is H, (1-4C)alkyl or (1-4C)alkenyl; and

R3 is H or (1-4C)alkyl, optionally substituted with one or more halogen; and R4 is cyclopropyl; or

R2 together with R3 forms a 3-, 4-, 5- or 6-membered carbocyclic ring; and R4 is cyclopropyl.

19. (Currently Amended) A compound according to claim 13, characterised in that wherein

A1, A3, A4 and A5 are C;

A2 is N;

R1 is H

R2 is methyl;

R3 is H;

R4 is cyclopropyl;

R5 is H.

20.	(Currently Amended) A compound according to claim 13, characterised in the wherein
	A1; A3, A4 and A5 are C;
	A2 is N;
	R1 is H
	R2 is ethenyl;
	R3 is H;
	R4 is cyclopropyl;
	R5 is H
21.	(Cancelled)
22.	(Currently Amended) A pharmaceutical composition comprising a compound
	according to any one of claims 1-20 claim 1 and a pharmaceutically acceptable
	carrier.
23.	(Cancelled)
24.	(Cancelled)
25.	(Cancelled)
26.	(Cancelled)
27.	(Cancelled).
28.	(Cancelled)
29.	(Currently Amended) A method of contraception comprising administering a pharmaceutically effective amount of a compound according to any one of claims 1-20 claim 1 to a subject in need thereof.
30.	(Currently Amended) A method of treating a gynaecological disorder comprising

31. (New) A method of hormone replacement therapy comprising administering a pharmaceutically effective amount of a compound according to claim 1 to a subject in need thereof.

any one of claims 1-20 claim 1 to a subject in need thereof.

administering a pharmaceutically effective amount of a compound according to